Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC).

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ARDIZZONI Andrea RAZIS Evangelia LICHINITSER Mikhail YILMAZ Ugur GRIGORESCU Alexandru MORERO Jusé Luis SKŘIČKOVÁ Jana CERVANTES Guadalupe GOTTFRIED Maya VAN MEERBEECK Jan

Year of publication 2007
Type Article in Proceedings
Conference Journal of Thoracic Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords Erlotinib; non-small cell lung cancer; drug safety; TRUST study
Description An international group of authors have published interim results concerning the drug safety of erlotinib, an anti-tumor drug used in treatment of patients with advanced non-small cell lung cancer within TRUST, a global open-label study of erlotinib.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info